Appointment of Mr. Yogainder Kumar Gupta (DIN:03094998) as Additional Director, Non-executive Independent Director on the Board of Directors of the Company w.e.f. 30th May 2025 for a period ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech's board, at its May 30, 2025 meeting, approved standalone audited financial results for Q4 and FY ended March 31, 2025, with the statutory auditor issuing an unmodified (clean) opinion. The company appointed Mr. Yogainder Kumar Gupta (44 years of finance and real estate experience) as an Additional Non-Executive Independent Director for a 5-year term till May 29, 2030, subject to shareholder approval. M/s. SBR & Co. LLP was appointed as Secretarial Auditor for FY24-25, and various board committees (Audit, SRC, NRC, Risk Management) were reconstituted. Key financials: FY25 revenue from operations jumped to ₹84.39 lakh (from ₹16.51 lakh in FY24), and FY25 net profit surged to ₹35.61 lakh (from ₹1.52 lakh), translating to EPS of ₹1.17 (vs ₹0.05). However, Q4 FY25 standalone showed a loss of ₹8.35 lakh despite revenue of ₹26.35 lakh.
A clean audit and sharply higher full-year profit and revenue are mildly positive signals for shareholders. The new independent director and committee reconstitution indicate governance housekeeping, while the Q4 loss highlights uneven quarterly performance. Stock-price impact is likely limited as this is a small-cap horticulture company on BSE.